BioCryst resumes enrollment for immune diseases drug; Eagle buys stake in respiratory disease biotech
In April, the FDA hit BioCryst with a partial hold, leading the biotech to pause enrollment on three of its rare disease clinical trials and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
